Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (13560)	10/27/2004 5:43:35 PM
From: former_pgs	Read Replies (1) \| Respond to of 52153

I think this is yet another update of their completed 9901 trial, the one that had the favorible Gleason < 7 subgroup. If it gets a bump up due to the data tomorrow, might be a nice quick short play. Their D9902B trial is the one that should materially affect valuation... it's prospectively designed to focus on the subgroup that showed benefit in the 9901 trial. I find it a curious situation because they keep expounding on the 9901 subgroup. Same conclusion, just slightly different numbers each time. I've stayed out of it.